No Data
Express News | Kymera Therapeutics Inc - KT-333 Phase 1 Study Ongoing With Additional Data Expected in Second Half of 2024
Kymera Therapeutics to Present New Clinical Data From the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual
Analysts Offer Insights on Healthcare Companies: Valneva (VALN), Janux Therapeutics Inc (JANX) and Kymera Therapeutics (KYMR)
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using target
Earnings Call Summary | Kymera Therapeutics(KYMR.US) Q1 2024 Earnings Conference
The following is a summary of the Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript:Financial Performance:Kymera reported Q1 2024 revenue of $10.3 million, solely from its collaboratio
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript